Abstract
On a model of neurodegeneration induced by neurotoxic peptide fragment (25–35) of β-amyloid (Aβ), we studied changes in the content of neurotrophins: insulin-like growth factor 1 (IGF-1) and nerve growth factor (NGF) in different brain areas, as well as the thymus, liver, and blood serum of rats under the influence of hypothalamic proline-rich peptide-1 (PRP-1). The effect of PRP-1 on the structural-functional state of the neurons was also studied. We showed that intramuscular injections of synthetic PRP-1 at a dose of 10 μg per 100 g of body weight for the first 9 days after intracerebroventricular administration of Aβ into the lateral brain ventricles of rats resulted in a considerable increase in the concentration of IGF-1 in all investigated brain structures, mainly, in the neocortex, hippocampus, and hypothalamus at 12 week of developing the neurodegeneration. This effect was maintained also after intramuscular administration of PRP-1 at 30 days after Aβ injection (a later date). However, as a result of PRP-1 action at early stages of the process, the tendency to decrease NGF content in the cortex, hippocampus and hypothalamus was observed. Electrophysiological and morphological studies of hippocampal neurons show, that by the 18th week after the beginning of neuro-degeneration, treatment with PRP-1 results in survival and further maintenance of cells, which indicates that PRP-1 has neuroprotective characteristics. We concluded that treatment with PRP-1 at Aβ-induced neuro-degeneration may provide normal functioning of neurons during a relatively long period of time by modulation the levels of neurotrophins both in brain and peripheria.
Similar content being viewed by others
References
Walsh, D.M., Klyubin, I., and Fadeeva, J.V., Biochem. Soc. Trans., 2002, vol. 30, no. 4, pp. 552–557.
LaFerla, F.M., Green, K.N., and Oddo, S., Nat. Rev. Neurosci, 2007, vol. 8, no. 7, pp. 499–509.
Ondrejcak, T., Klyubin, I., Hu, N.W., Barry, A.E., Cullen, W.K., and Rowa, M.J., Neuromolecular Med, 2010, vol. 12, no. 1, pp. 13–26.
Rivera, E. and Noah Fulmer, A., J. Alzheimers D., vol. 8, no. 3, p. 247–268.
Tuszynski, M.H., Thal, L., Pay, M., Salmon, D.P, U, H.S, Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G., Tong, G., Potkin, S.G., Fallon, J., Hansen, L., Mufson, E.J., Kordower, J.Hu., Gall, C., and Conner, J., Nat. Med, 2005, vol. 11, no. 5, pp. 551–555.
Blesch, A., Uy, H.S., Grill, R.J., Cheng, J.G., Patterson, P.H., and Tuszynski, M.H., J. Neurosci., 1999, vol. 19, no. 9, pp. 3556–3566.
Jones, J.I. and Clemmons, D.R., Endocrinol. Rev, 1995, vol. 16, no. 1, pp. 3–34.
Trejo, J.L., Carro, E., and Torres-Aleman, I., J. Neurosci., 2001, vol. 21, no. 5, p. 1628–1634.
Carro, E., Trejo, J.L., Nu≠z, A., and Torres-Aleman, I., Mol. Neurobiol, 2003, vol. 27, no. 2, pp. 153–162.
Yuan, J. and Yankner, B.A., Nature, 2000, vol. 407, no. 6805, pp. 802–809.
Carro, E., Trejo, J., Gerber, A., Loetscher, H., Torrado, J., Metzger, F., and Torres-Aleman, I., Neurobiology of Aging, 2005, vol. 27, no. 9, pp. 1250–1257.
Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., Torres-Aleman, I., Nat. Med., 2002, vol. 8, no. 12, pp. 1390–1397.
Trejo, J.L., Carro, E., Garcia-Galloway, E., and Torres-Aleman, I., J. Molec. Med., 2004, vol. 82, no. 3, pp. 156–162.
Mufson, E.J., Conner, J.M., and Kordower, J.H., Neuroreport, 1995, vol. 6, no. 7, pp. 1063–1066.
Fahnestoc, M., Scott, S.A., Jette, N., Weingartne, J.A., and Crutche, K.A., Mol. Brain Res., 1996, vol. 42, no. 1, pp. 175–178.
Galoyan, A., Neurochem. Res, 2000, vol. 25, nos. 9–10, pp. 1343–1355.
Galoyan A., Brain Neurosecretory Cytokines. Immune Response and Neuronal Survival, New York: Kluwer Academic, 2004, pp. 1–188.
Gladkevich, A., Bosker, F., Korf, J., Yenkoyan, K., Vahradyan, H., and Aghajanov, M., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, vol. 1, no. 7, pp. 1347–1355.
Yenkoyan, K., Safaryan, K., Chavushyan, V., Meliksetyan, I., Navasardyan, G., Sarkissian, J., Galoyan, A., and Aghajanov, M., Brain Res. Bull., 2011, vol. 86, nos. 3–4, pp. 262–271.
Galoyan, A.A., Sarkissian, J.S., Chavushyan, V.A., Meliksetyan, I.B., Avagyan, Z.E., Poghosyan, M.V., Vahradyan, H.G., Mkrtchian, H.H., and Abrahamyan, D.O., Alzheimers Dement., 2008, vol. 4, no. 5, pp. 332–344.
Galoyan, A.A., Shakhlamov, V.A., Aghajanov, M.I., and Vahradyan, H.G. Neurochem. Res., 2004, vol. 29, no. 7, pp. 1349–1357.
Galoyan, A.A, Sarkissian, J.S, Kipriyan, T.K., Sarkissian, E.J., Chavushyan, E.A., Sulkhanyan, R.M., Meliksetyan, I.B., Abrahamyan, S.S., Griorian, Y.Kh., Avetisyan, Z.A., and Otieva, N.A., Neurochem. Res., 2001, vol. 26, nos. 8–9, pp. 1023–1038.
Paxinos, G. and Watson, Ch., The Rat Brain in Stereotaxic Coordinates: Compact 6th Edition, New York: Academic Press., 2005.
Mauric, T., Lockhar, B., Su, T., and Privat, A., Brain Res., 1996, vol. 731, nos. 1–2, pp. 249–253.
Meliksetyan, I.B., Morfologiya, 2007, vol. 131, no. 6, pp. 77–80.
Palkovits, M. and Brownstein, M., Appleton and Lange, 1988, p. 223.
Wes, M.J., Coleman, P.D., Flood, D.G., and Troncoso, J.C., Lancet, 1994, vol. 344, no. 8925, pp. 769–772.
Gallagher, M. and Koh, M.T., Current Opinion in Neurobiology, 2011, vol. 21, no. 6, pp. 929–934.
Yenkoyan, K., Safaryan, K., Navasardyan, G., Mkrtchyan, L., and Aghajanov, M. Neurochem. Int., 2009, vol. 54, nos. 5–6, pp. 292–298.
Rosenfeld, R.G., Pham, H., Keller, T., Borchardt, R.T., and Pardridge, W.M. Biochem. Biophys. Res. Commun., 1987, vol. 49, no. 1, pp. 159–166.
Frank, H.J., Pardridg, W.M., Morri, W.L., Rosenfeld, R.G., and Choi, T.B. Diabetes, 1986, vol. 5, no. 6, pp. 654–661.
Tham, A., Nordberg, A., Grissom, F.E., Carlsson-Skwirut, C., Viitanen, M., and Sara, V.R., J. Neural. Transm. Park Dis. Dement. Sect, 1993, vol. 5, no. 3, p. 165–176.
Torres-Aleman, I., Mol. Neurobiol, 2000, vol. 21, no. 3, pp. 153–160.
Nuñez, A., Carro, E., and Torres-Aleman, I., J. Neurophysiol., 2003, vol. 89, no. 6, pp. 3008–3017.
Nuñez, A. and Buño, W., Eur. J. Neurosci, 1999, vol. 11, no. 6, pp. 186–1876.
Hoffman, D.A., Magee, J.C., Colbert, C.M., and Johnston, D., Nature, 1977, vol. 387, no. 6636, pp. 869–875.
Sofroniew, M.V., Howe, C.L., and Mobley, W.C., Annu. Rev. Neurosci., 2001, vol. 24. pp. 1217–1281.
Jung, KM., Tan, S., Landman, N., Petrova, K., Murray, S., Lewis, R., Kim, P.K., Kim, D.S., Ryu, S.H., Chao, M.V., and Kim, T.W., J. Biol. Chem., 2003, vol. 278, no. 43, pp. 42161–42169.
Roux, P.P. and Barker, P.A., Prog. Neurobiol, 2002, vol. 67, no. 3, pp. 203–233.
Rabizadeh, S. and Bredesen, D.E., Cytokine Growth Factor Rev, 2003, vol. 14, nos. 3–4, pp. 225–239.
Hazari, M.S., Pan, J.H., and Myers, A.C., Am. J. Physiology Lung Cell Mol. Physiol., 2007, vol. 292, no. 4, pp. L992–L1001.
Wasling, P., Daborg, J., Riebe, I., Andersson, M., Portelius, E., Blennow, K., Hanse, E., and Zetterberg, H., J. Alzheimers D., vol. 16, no. 1, pp. 1–14.
Palop, J.J. and Mucke, L., Nature Neuroscience, 2010, vol. 13, no. 7, pp. 812–818.
Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O., Yu, G.Q., Kreitzer, A., Finkbeiner, S., Noebels, J.L., and Mucke, L., Neuron, 2007, vol. 55, no. 5, pp. 697–711.
Bruno, M.A., Leon, W.C., Fragoso, G., Mushynski, W.E., Almazan, G., and Cuello, A.C., J. Neuropathol. Exp. Neurol., 2009, vol. 68, no. 8, pp. 857–869.
Thoenen, H., Prog. Brain Res., 2000, vol. 128, pp. 183–191.
Paredes, D., Granholm, A.C., and Bickford, P.C., Brain Res., 2007, vol. 1141, pp. 56–64.
Auld, D.S., Mennicken, F., and Quirion, R., J. Neurosci., 2001, vol. 21, no. 10, p. 3375–3382.
Kelsch, W., Hormuzdi, S., Straube, E., Lewen, A., Monyer, H., and Misgeld, U., J. Neurosci., 2001, vol. 21, no. 21, pp. 8339–8347.
Gonzalez de la Vega, A., Buño, W., Pons, S., Garcia-Calderat, M.S., Garcia-Galloway, E., and Torres-Aleman, I., Neuroreport, 2001, vol. 12, no. 6, pp. 1293–1296.
Wan, Q., Xiong, Z.G., and Man, H.Y., Nature, 1997, vol. 388, no. 6643, pp. 686–690.
Fadool, D.A., Tucker, K., Phillips, J.J., and Simmen, J.A., J. Neurophysiol., 2000, vol. 83, no. 4, pp. 2332–2348.
Carro, E., Nuñez, A., Busiguina, S., and Torres-Aleman, I., J. Neurosci., 2000, vol. 20, no. 8, pp. 2926–2933.
Garcia-Galloway, E., Arango, C., Pons, S., and Torres-Aleman, I., Mol. Cell. Neurosci., 2003, vol. 24, no. 4, pp. 1027–1037.
Xie L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., and Martins, R., J. Neurosci., 2002, vol. 22, no. 10 (RC221), pp. 1–5.
Ullrich, A., Gray, A., Tam, A.W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., and Chen, E., EMBO J., 1986, vol. 5, no. 10, pp. 2503–2512.
Gasparini, L., Netzer, W.J., Greengard, P., and Xu, H., Trends. Pharmacol. Sci., 2002, vol. 23, no. 6, pp. 288–293.
Jain, S., Golde, D.W., Bailey, R., and Geffner, M.E., Endocr. Rev., 1988, vol. 19, no. 5, pp. 625–646.
Buhler, A.V. and Dunwiddie, T.V., J. Neurophysiol., 2002, vol. 87, no. 1, pp. 548–557.
Ge, S. and Dani, J.A., J. Neurosci, 2005, vol. 25, no. 26, pp. 6084–6091.
Bak, L.K., Schousboe, A., and Waagepetersen, H.S., J. Neurochem., 2006, vol. 98, no. 3, pp. 641–653.
Mathews, G.C. and Diamond, J.S., J. Neurosci., 2003, vol. 23, no. 6, pp. 2040–2048.
Mann, E.O. and Paulsen, O., Trends Neurosci., 2007, vol. 30, no. 7, pp. 343–349.
Rissman, R.A., De Blas, A.L., and Armstrong, D.M., J. Neurochem., 2007, vol. 103, no. 4, pp. 1285–1292.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © M.I. Aghajanov, K.B. Yenkoyan, V.A. Chavushyan, J.S. Sarkissian, 2014, published in Neirokhimiya, 2014, Vol. 31, No. 1, pp. 58–70.
Rights and permissions
About this article
Cite this article
Aghajanov, M.I., Yenkoyan, K.B., Chavushyan, V.A. et al. The proline-rich hypothalamic peptide is a modulator of functions of neurotrophins and neuronal activity in amyloid-induced neurodegeneration. Neurochem. J. 8, 47–57 (2014). https://doi.org/10.1134/S1819712414010036
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712414010036